Cite
MLA Citation
Stanley B. Cohen et al.. “Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext).” Expert opinion on biological therapy, vol. 19, 2019, pp. 1097–1105. http://access.bl.uk/ark:/81055/vdc_100101545511.0x000035